Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs including vasomotor symptoms (VMSs), musculoskeletal adverse events (MSAEs), and vulvovaginal symptoms (VVSs) in postmenopausal patients with breast cancer participating in the international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
INTRODUCTION
Since the 1980s, adjuvant endocrine therapy by means of tamoxifen, a selective estrogen receptor modulator, has been a beneficial agent for patients with breast cancer, being most effective in hormonesensitive breast cancer. 1, 2 Later, 5 years of tamoxifen therapy became the gold standard for adjuvant endocrine treatment. Over the last 15 years, several studies have been performed to assess the value of third-generation aromatase inhibitors, showing benefit in terms of overall survival (OS), disease-free survival (DFS), distant disease-free survival, and contralateral breast cancer recurrence in postmenopausal patients with breast cancer who have hormone receptor-positive disease when compared with tamoxifen. [3] [4] [5] Other studies showed beneficial effects of a sequential treatment regimen consisting
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O R I G I N A L R E P O R T of 2 to 3 years of tamoxifen followed by 2 to 3 years of an aromatase inhibitor when compared with tamoxifen alone. 3, 4, 6, 7 Both tamoxifen and aromatase inhibitors are associated with inconvenient and sometimes debilitating adverse effects resembling menopausal symptoms and which may be related to lower levels of peripherally circulating estrogens or blocking of the estrogen receptor (ER) in particular tissues, depending on the type of endocrine therapy used. [8] [9] [10] [11] Some relevant and commonly reported adverse events (AEs) associated with adjuvant endocrine therapy for early breast cancer comprise vasomotor symptoms (VMSs), musculoskeletal and joint symptoms (MSAEs), and vulvovaginal symptoms (VVSs). After menopause, estrogen production is derived from peripheral tissues including adipose tissue, muscle, liver, skin, brain, bone marrow, and breast tissue. 12, 13 VMSs are a well-known adverse effect of estrogen deprivation, occurring both naturally during menopause and artificially in relation to chemotherapy and endocrine therapy administered in patients with early breast cancer. 11 Estrogen is considered a factor that affects temperature regulation by promoting vasodilation, which influences blood flow to the skin. 14 Through decreased estrogen levels associated with endocrine therapy, the body lacks the ability to maintain normal body temperatures. 15 Estrogen deprivation has also been linked to the development of MSAEs in patients on endocrine therapy.
9 Estrogen has antinociceptive effects that influence the body's sensitivity to pain in articular structures as well as increased levels of proinflammatory cytokines, which is thought to be associated with MSAEs.
9,16 With respect to VVSs, aromatase inhibitors (further) lower postmenopausal estrogen levels, causing vaginal atrophy, and possibly resulting in vaginal dryness and dyspareunia. 17, 18 Tamoxifen, however, has known agonist effects on the uterus. 19, 20 Adverse effects during long-term treatment can significantly impact quality of life as well as treatment compliance. Earlier studies on adjuvant breast cancer therapy recognized that noncompliance is largely attributable to the presence of adverse effects. [21] [22] [23] [24] [25] Furthermore, treatment outcomes can be compromised when adjuvant endocrine treatment is not taken for the full prescribed duration. 26 In earlier reports, the relationship between vasomotor as well as musculoskeletal symptoms and breast cancer recurrence in patients treated with adjuvant endocrine therapy was investigated. 27, 28 The presence of both symptoms was predictive of fewer breast cancer recurrences. Recently, we reported results of Dutch and Belgian exemestane-only patients and found a significant relapse-free survival (RFS) benefit in patients who reported VMSs and MSAEs. 29 Similarly, a recent investigation by Huober et al 30 in the Breast International Group 1-98 trial found associations between arthralgia, myalgia, and vasomotor symptoms and improved DFS. Stearns et al, 31 however, also investigated the association between endocrine symptoms and RFS in the MA27 trial, but did not find a benefit in patients who reported VMSs and/or MSAEs. Another issue is that patients treated with either tamoxifen or aromatase inhibitors commonly complain of VVSs. Vaginal dryness was addressed in the study by Huober et al, 30 categorized as one of the VMSs. To the author's knowledge, no other reports exist on the relationship between VVSs and breast cancer recurrence.
In the present analysis, we investigated the relationship between specific AEs (VMSs, MSAEs, and VVSs) arising in the first year of endocrine therapy and treatment efficacy in postmenopausal patients with early breast cancer enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. In addition, the influence of early treatment discontinuation within the 5-year treatment period in relation to outcome in patients with and without specific AEs was assessed.
PATIENTS AND METHODS

TEAM Trial
The TEAM trial is a randomized, phase III, multinational, open-label study conducted in postmenopausal women with ER and/or progesterone receptor-positive breast cancer and who were eligible for adjuvant endocrine treatment. Patients were randomly assigned to receive either exemestane 25 mg once daily for 5 years or tamoxifen 20 mg once daily for 2.5 to 3 years, followed by exemestane 25 mg once daily for 2.5 to 2 years (sequential regimen).
6 Participants were enrolled in 599 hospitals in nine countries worldwide (Belgium, France, Germany, Greece, Japan, the Netherlands, United Kingdom and Ireland, and the United States).
6 Similar trial protocols were used in all countries, with minor differences to accommodate the regional treatment guidelines; the TEAM trial protocols were approved by the regulatory and ethics authorities of all participating centers in all participating countries. 6 All patients provided written informed consent, and additional consent was obtained from patients using tamoxifen for the switch to exemestane. The study was conducted in compliance with the guidelines of the Declaration of Helsinki, International Conference on Harmonisation, and Good Clinical Practice. Appropriate approvals from the ethical committee were obtained. 6 Data collection was performed locally by case report forms and regularly transferred to a local data center, after which the Central Statistical and Data Center collected and analyzed the pooled data. Follow-up was carried out every 3 months in the first year and twice yearly until year 5 (end of randomized therapy), with yearly mammography. Details of eligibility criteria have been published in earlier reports. 6 In the TEAM trial, 9,766 patients were allocated to 5 years of exemestane or to a sequential treatment with tamoxifen followed by exemestane for a total of 5 years in the TEAM trial. For the current analyses, we excluded patients who did not start the randomized treatment, who discontinued their allocated therapy within the first year, or who had an event (recurrence or death) within the first year of starting endocrine therapy.
AEs
All AEs reported in the first year of starting adjuvant endocrine therapy were included in the analyses. AEs were obtained from patient responses during follow-up visits, and a standard symptom checklist was not used. Severity of AEs was assessed using the National Cancer Institute Common Toxicity Criteria and were centrally recoded using the Medical Dictionary for Regulatory Activities (version 12.1). 6 VMSs were defined as a subjective and transient sensation of heat, including hot flashes and night sweats. MSAEs were all accounts of arthralgia, arthritis, arthrosis, myalgia, and bone pain. For the current analysis, osteoporosis was not considered an MSAE due to the fact that osteoporosis is a long-term process, likely to take more than 1 year to become evident. VVSs included all accounts of vaginal dryness/itching, vaginal discharge, dyspareunia, and endometrial and libido disorders.
End Points
The efficacy end points of the present investigation were DFS, OS, and distant metastases (DM), starting as of the second year of therapy. DM comprised all cases of metastases of the skeleton, skin, liver, lung, brain, and contralateral lymph nodes and excluded locoregional recurrences (including ipsilateral breast cancer, ipsilateral lymph nodes, ipsilateral chest wall recurrences), contralateral breast cancer, and new primary tumors. DFS was defined as the time on treatment to the earliest documentation of disease relapse or death (all causes) or end of follow-up, whichever came first. OS was defined as the time on treatment to the date of death.
The relationship between the occurrence of specific AEs (VMSs, MSAEs, and VVSs) and survival and recurrence outcomes was assessed. Furthermore, we evaluated the relationship between outcome measures and the sum of the different kinds of specific AEs reported per patient.
Statistical Analysis
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL). It was possible to combine the patients in the two treatment groups, as the primary efficacy analysis found no differences in outcome between the two treatment arms. 6 Landmark analyses were conducted, with follow-up starting at 1 year after randomization. Accounts of specific AEs reported in the first year after randomization were used to classify patients into the yes/no cohorts for VMSs, MSAEs, and VVSs. Kaplan-Meier curves were plotted for time to event. Early treatment discontinuation is an important factor in patients who experience AEs of endocrine treatment, as shorter time on treatment may negatively influence outcomes. 26 Multivariate time-dependent Cox proportional hazards models with specific adverse event (yes/no), on treatment (yes/no), and their interaction assessed differences in survival with respect to the presence or absence of VMSs, MSAEs, and VVSs, in relation to time on treatment. All multivariate analyses were adjusted for age at diagnosis, country, histologic grade, tumor size, nodal stage, most extensive surgery, radiotherapy, and chemotherapy. Interaction terms between adverse symptoms and all previously mentioned adjusted variables were incorporated in the Cox model to test for the presence of effect modification.
RESULTS
Study Population
In total, 9,325 patients (95%) were included in the current analyses; reasons for exclusion are shown in Figure 1 . We excluded patients who never started treatment or who had an unknown start date (n ϭ 93) and patients who discontinued their allocated therapy (n ϭ 174) or who had an event (recurrence or death) within the first year of treatment (n ϭ 174). A total of 4,694 patients were allocated to receive 5 years of exemestane, and 4,631 patients were allocated to receive the sequential treatment regimen. Median follow-up was 5.13 years (range, 0.01 to 9.23 years), and median age was 63.8 years (range, 34.9 to 96.1 years). Baseline characteristics were similar between the two treatment groups. 6 Baseline characteristics of the patients who reported specific AEs versus none or nonspecific AEs are shown in Table 1 . Overall, there was no difference in the presence of specific versus none or nonspecific AEs between randomized treatments. Assessed separately, patients allocated sequential treatment reported fewer VMSs and MSAEs, but more VVSs ( 2 P Ͻ .001 for all comparisons). Younger patients were more likely to report specific AEs, whereas older patients were more likely to report nonspecific AEs (Ͻ 60/60 to Ͻ75/Ն 75 years: 16.3%/ 22.2%/31.5% nonspecific AEs reported, respectively). In addition, patients who reported specific AEs more frequently had welldifferentiated and low-grade tumors, had node-negative disease, underwent breast-conserving surgery, and had adjuvant radiotherapy Table 2 ).
DMs
Further investigations into the occurrence of VMSs and MSAEs in relation to DM revealed that patients who reported these symptoms had fewer accounts of DM than when these symptoms were not reported (multivariate HR for VMSs: 0.813 [95% CI, 0.664 to 0.996[; MSAE: 0.749 [95% CI, 0.601 to 0.934[). VVSs were associated with significantly fewer DMs after univariate analyses, but not for multivariate analyses (Table 2 ). There was no effect modification for treatment discontinuation and the risk of DM for VMSs, MSAEs, and VVSs (Table 2) .
Early Treatment Discontinuation
Time-dependent Cox regression analyses were performed to investigate the relationship between time on treatment and survival outcomes. Pertaining to VMSs and MSAEs, treatment discontinuation did not affect the improved DFS and OS in patients who reported these specific AEs. Therefore, even if patients discontinued treatment before the predesignated stop date (which was 5 years after the start of randomized therapy), a survival benefit persisted in those who reported specific AEs. This was also the case for DFS in relation to VVSs, but not for OS (P for interaction ϭ .016; Table 2 ).
Sum of Specific AEs
A patient could have a maximum of three types of specific AEs, which was the sum of VMSs, MSAEs, and VVSs (yes/no outcome). Improved outcomes for DFS, OS, and DM were found for increasing numbers of specific AEs reported (Table 3 ; Fig 3) . Outcomes for disease-free survival, overall survival, and distant metastases in relation to specific adverse events (AEs). HR, hazard ratio; MSAE, musculoskeletal adverse events; VMS, vasomotor symptoms; VVS, vulvovaginal symptoms. 
Adjuvant Chemotherapy in Relation to Specific AEs
Patients who received adjuvant chemotherapy more frequently reported specific AEs when compared with patients who had not been treated with adjuvant chemotherapy (56.3% v 43.7%; P Ͻ .001). There is a known relationship between adjuvant chemotherapy and menopausal symptoms, although the relation with late-onset symptoms has not been fully investigated. 32 We tested for effect modification by chemotherapy for VMSs and VVSs and MSAEs. No effect could be demonstrated (data not shown).
DISCUSSION
The present analyses showed that postmenopausal patients with breast cancer who received at least 1 year of adjuvant endocrine therapy and who reported one or more treatment-related AEs during the first year of treatment had better subsequent outcomes in terms of DFS and OS and fewer DMs than patients who do not report these symptoms. The strongest effect on distant recurrence and survival outcomes was observed for VMSs. A decreasing incidence of distant metastases, disease relapse, and death was noted in patients reporting increasing numbers of different specific AEs. Furthermore, even if patients who reported specific AEs were not on treatment for the full duration, they still had better outcomes than patients who were on treatment for longer, but did not experience specific AEs. No difference in effect was found between the two TEAM trial treatment arms. The present investigation only included patients who reported symptoms in the first year of endocrine therapy. Because of the unplanned nature of these analyses, preexisting symptoms were not recorded. The effect observed may therefore be larger when the occurrence of specific AEs over the entire follow-up period is considered. Reporting of AEs may not be uniform across countries or study centers within countries; therefore, it is conceivable that results may be influenced by reporting bias. The incidence of reported specific AEs varied considerably by country, and survival outcomes were better in countries where more specific AEs were reported (Appendix Table A1 , online only). These results must be interpreted with caution, as no information was available for individual study centers. All AEs were patient-reported AEs, and no standardized symptom checklist was used. Cultural differences between countries may therefore also reflect differences in reporting of AEs. A symptom checklist that actively inquires about a patient's symptoms and severity thereof will undoubtedly lead to a more accurate assessment and potentially observe a stronger relationship between specific AEs, severity, and improved outcomes. Also of note, characteristics of patients reporting specific versus no or nonspecific AEs revealed that patients with specific AEs were younger, more frequently had lower-grade tumors and nodenegative disease, and underwent breast-conserving surgery and adjuvant radiotherapy and chemotherapy. Although it is conceivable that older patients may be less likely than younger patients to report any AE at all, older patients reported more nonspecific AEs than younger patients in our cohort. Nonetheless, even after adjusting for these possible confounders, the correlation between specific AEs and superior outcomes was still present.
Previously, a relationship was found between VMSs and MSAE and disease recurrence in patients with breast cancer participating in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial 27 and between hot flashes and outcomes in tamoxifen-treated patients in a study by Mortimer et al. 28 Our earlier manuscript regarding Dutch and Belgian exemestane users reports a relationship between MSAEs and VMSs and disease recurrence. 29 In the current analyses, we aimed to assess whether results varied in a much more heterogeneous population. Minor variations in protocols between countries accommodated regional treatment guidelines. Additionally, in the context of cultural differences between countries, variations in reporting may exist. Most importantly, however, we address time on treatment in relation to the occurrence of AEs. In contrast to what is generally expected, Cuzick et al 27 noted a better treatment adherence in patients experiencing vasomotor and joint symptoms. However, noncompliance resulting from adverse effects plays an important role in adjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive breast cancer, and several studies have reported that patients who discontinue treatment before the predesignated end date do so largely because of AEs. [21] [22] [23] [24] [25] Patients who discontinue the prescribed treatment regimen may not enjoy the full benefit of treatment as a result of shorter time on treatment. 26 Pritchard sharply points out that the reporting of AEs may depend on the kind of patient who reports these symptoms; this may be related to treatment compliance, which would hence explain improved treatment outcomes in these patients. 33 Similarly, patients who do not report specific AEs may not have taken the prescribed treatment. Therefore, we performed a time-dependent Cox regression analysis for time on and off treatment. The positive effect of specific AEs on outcomes did not change for patients who went off treatment. Accordingly, even if patients who experience specific AEs discontinued treatment before the designated stop date, they still had a survival benefit over patients who did not experience specific AEs.
Although our results must be considered hypothesis generating, our findings show an association between specific adverse effects caused by endocrine therapy and outcomes and may thus potentially be a valuable predictor and biomarker of treatment efficacy. Future prospective studies, however, are warranted to advance the personalization of treatment strategies for patients with breast cancer.
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